Connect with us

Published

on

Using GLP-1s drug injections for weight loss has become one of the latest ways some big names in the market are shedding extra pounds. Elon Musk recently tweeted about how using Novo Nordisk’s Wegovy helped him lose weight. Fanatics CEO Michael Rubin recently told CNBC’s “Squawk Box” that using a different version of Novo Nordisk’s same drug, Ozempic, which is most commonly associated with diabetes care, made him much less hungry.

“The weekly shot is amazing. … I started this about a year ago, it’s been life changing for me,” Rubin said. 

Social media influencer Remi Bader said she was prescribed Ozempic after experiencing issues with insulin and weight gain.

GLP-1s — which stands for glucagon-like peptide-1 — are receptor agonists that work by imitating the effects of the GLP-1 hormone, activating GLP-1 receptors inside of the pancreas and producing more insulin inside the body. The insulin helps lower blood sugar levels, which can be helpful in managing Type 2 diabetes. GLP-1s also have been found to help with weight loss as they make individuals who use them feel fuller for a longer period of time.

It’s not only the GLP-1 drugs that are helping celebrities and the wealthy, but also their ability to receive high quality clinical and obesity care that helps them lose the weight, according to Zachariah Reitano, the co-founder and CEO of telehealth company Ro. That’s why his company has launched a program to offer GLP-1 drugs and corresponding medical care to individuals struggling with obesity or weight loss issues.

“I think what we’re able to do now is leverage all of the technology that we have to give everyone access to something that only a few people have access to now,” Reitano said in a recent interview with CNBC. 

Ro’s Body Program offers personalized treatment for GLP-1s and weight management. The year-long program uses a combination of GLP-1s and personal coaching. In clinical trials, these drugs have helped participants lose an average of 15% of their weight over a year.

Pairing personalized coaching with GLP-1s is the key to effective weight loss treatment, Reitano said, and helping patients maximize their results.

“I think what’s really important is, yes, it’s access to the medication … but once they have the medication, we want to hold their hand throughout the entire process, and we have built the technology to be able to do that at scale,” Reitano said.

With the Ro Body Program, participants are first diagnosed, entering information about their health history, any weight loss and obesity challenges, and lifestyle and diet, and then are sent an at-home lab test to obtain measures of A1C blood sugar test, cholesterol and kidney function, among other health metrics. Based on their test results and an initial consultation, a doctor may prescribe patients to start off with a low dosage of GLP-1s that is slowly ramped up over time to meet the desired dosage amount.

Diabetes, obesity and a nationwide drug controversy

Ozempic – the brand of semaglutide, a GLP-1 receptor agonist, marketed for Type 2 diabetes treatment – recently made headlines for a nationwide shortage as its use as a weight loss drug gained popularity. When Wegovy, the brand semaglutide marketed for weight management, began experiencing shortages, some using the medicine were prescribed off-brand Ozempic, makin the drug much harder to find. Many with Type 2 diabetes that relied on Ozempic to treat it have been left scrambling to find the medication. There have also been reports of people looking for weight loss help turning to multiple other drug solutions as a result of difficulty finding GLP-1 drugs.

Both obesity and Type 2 diabetes affect a large number of Americans. According to the CDC, the adult obesity rate in the United States was 41.9% in 2017, and about one in 10 people in the United States have Type 2 diabetes. Reitano said it is important to recognize both obesity and diabetes as diseases that deserve proper treatment.

“I think what we’re actually going to see over the next 5 to 10 years is a weight-centric approach to metabolic health,” Reitano said, who noted in a subsequent interview with CNBC’s “Mad Money” on Thursday night that his father’s personal experience with GLP-1 drugs was a motivating factor for his business decision. “I’ve seen GLPs have a tremendous impact on my dad,” he said.

He told CNBC’s Jim Cramer that the once a week injections do three “very, very important things” when comes to obesity. They help regulate sugar levels; they help regulate appetite; and they slow the passage of food from the stomach to the small intestine. This combination of controls has helped patients in clinical studies lose on average 15% of body weight over a year.

Novo Nordisk, Ozempic and Wegovy’s manufacturer, told NBC News last week the company is still experiencing supply chain issues that will last through the month, though access to some dosages of Ozempic for patients with Type 2 diabetes has improved.

The GLP-1 drug Wegovy for weight issues or obesity is approved for individuals with a BMI of 26-plus and co-morbidities, or those with a BMI of 30-plus.

A new real-time approach to weight management

Reitano said it should not be an either/or scenario involving diabetes management of weight loss and that will change over the next decade.

“If we saw obesity as a disease, and we’re both focused on preventing it but once it happens treating it and treating it as a disease, I think we’re going to see an entirely different approach,” he said.

Reitano said the weight loss and obesity management program fits within his company’s broader goal of changing the way patients receive medical care and reach health goals, from doctor visits to pharmacy and ongoing health issue management.

“High-quality obesity care is an important part of it,” he told Cramer. “Patients can’t just receive these medications and be left to their own devices.”

In addition to shipping the GLP-1 drug to a patient’s home, the Ro Body program tracks patients in real-time with remote monitoring. That is facilitated by a cellular-connected smart scale also sent to the patient which tracks weight and sends data to an app so medical professionals can tweak dosages of the drugs to make sure the patient is receiving the right dose to achieve the weight loss results they want. Patients also receive one-to-one coaching with nurses over the year-long period and up to 24 telehealth visits with a doctor.

“The speed with which we can communicate with patients, update their plans and really be there for them and guide them through this experience, and have that serve as a really strong compliment to their overall primary care, is one of the things I think we’re really excited about,” Reitano said in a recent phone interview with CNBC.

Price of these drugs, though, is an issue, with Wegovy costing as much as $1,700 a month without insurance. Reitano said Ro helps guide individuals through the insurance process and to get these drugs at the lowest price, but he conceded in his “Mad Money” interview that pricing in this pharmaceutical niche “can be challenging for patients.”

The Ro Body Program is the latest addition to Ro’s health care offerings. The company, which ranked No. 38 on the 2022 CNBC Disruptor 50 list, started off selling men’s health care products, helping to treat issues such as erectile dysfunction and hair loss, and has since expanded to provide multiple at-home services including pharmaceutical and fertility treatments. 

CNBC is now accepting nominations for the 2023 Disruptor 50 list – our 11th annual look at the most innovative venture-backed companies. Learn more about eligibility and how to submit an application by Friday, Feb. 17.

Continue Reading

Technology

These little robots are changing the way solar farms are built, saving time and money

Published

on

By

These little robots are changing the way solar farms are built, saving time and money

Clean energy gets a robot boost

Private renewable energy projects are still moving forward despite a pullback in government support, and new technology is making that construction more efficient.

Solar farms, for example, take meticulous planning and surveying, involve long hours and require significant labor. Now, robots are taking on the job.

CivDot is a four-wheeled robot that can mark up to 3,000 layout points per day and is accurate within 8 millimeters. The machine can ride over rugged terrain and work through rough weather.

It is the brainchild of California-based Civ Robotics.

“Our secret sauce and our core technology is actually in the navigation and the geospatial — being able to literally mark coordinates within less than a quarter inch, which is very, very difficult in an uneven terrain, outdoor surfaces, and out in the desert,” said Tom Yeshurun, CEO of Civ Robotics.

The data for manual surveying is uploaded into the Civ software, then the operator chooses the area they want to mark and presses go. The robot does the rest, saving both time and money.

Read more CNBC tech news

“The manual surveying equipment, if you use that in the field and you have three crews, they will need three land surveying handheld receivers. That alone is already equal to how much we lease our machines in the field, and all the labor savings is just another benefit,” Yeshurun said.

Civ Robotics has more than 100 of these robots in the field that are primarily being used by renewable energy companies, but they are also used in oil and gas. It is currently working with Bechtel Corporation on several solar projects.

“These were usually pretty highly paid field engineers that we would send out there, and they might be able to do 250 or 350 pile marks a day. With the CivDot robot, we’re able to do about 1250 a day,” said Kelley Brown, vice president at Bechtel.

Brown said the company has used the robot in thick and muddy terrain in Texas and out in the deserts of Nevada.

“And so you have to think about things like the tires, or you may have to think about clearance. Are you trying to get over existing brush and such, across the solar field? So that’s one thing that we contemplate. I think the other is, you know, this runs on batteries, so you’ve got to contemplate battery swaps,” she added.

Civ Robotics is backed by Alleycorp, FF Venture Capital, Bobcat Company, Newfund Capital, Trimble Ventures, and Converge. Total VC funding to date is $12.5 million.

There are other robotics solutions for markings, but the competition is mostly doing work on highways and soccer fields. Yeshurun said those rivals can’t handle the terrains that the solar industry faces as it expands into new territories.

 CNBC producer Lisa Rizzolo contributed to this piece.

Continue Reading

Technology

Sony raises PlayStation 5 prices in U.S. as tariffs start to hit

Published

on

By

Sony raises PlayStation 5 prices in U.S. as tariffs start to hit

The PlayStation DualSense controller and PlayStation 5 console.

Jakub Porzycki | Nurphoto | Getty Images

PlayStation 5 game consoles will cost $50 more in the U.S. starting this week, Sony announced on Wednesday.

The price for an entry-level PlayStation 5 Digital Edition will increase from $450 to $500, and a PlayStation 5 with a disc drive is going up to $550 from $500. Sony’s high-end PlayStation 5 Pro will cost $750, up from $700. The PlayStation 5 was first released in 2020.

President Donald Trump’s sweeping tariff plan announced in April went into effect earlier this month on most countries. The U.S. currently has a 30% tariff on imports from China, and higher tariffs on goods from the world’s second-largest economy are currently “paused,” according to the administration. Sony’s home country of Japan was hit with a 15% tariff.

While Sony didn’t attribute the increase to Trump’s tariffs, consumer companies have been warning for months that higher prices are on the way.

“Similar to many global businesses, we continue to navigate a challenging economic environment,” Sony said in its blog post.

The company said that retail prices for console accessories such as controllers haven’t changed.

Earlier this month, Sony officials said the company was working on supply chain diversification to combat U.S. tariffs, and said that the console hardware it sells in the U.S. is produced outside of China.

“It is difficult to speak to our hardware pricing strategy as that has implications for our future competitive strategy,” ” Sony officials said, according to a translated transcript of a call with financial analysts posted on its website. “But we intend to take a flexible approach to such decision-making by monitoring consumer price sensitivity as we think about total full-year segment profits, lifetime value, manufacturing, units sold in, and our content sales potential.”

In May, Microsoft raised the price of its Xbox video game consoles. Nintendo delayed pre-orders of its Switch 2 by a few weeks in April, attributing the delay to tariffs. Although Nintendo did not raise the price of its new consoles, it hiked the price of the original Switch earlier this month.

WATCH: Nintendo President on the new Switch 2, tariffs and what’s next for the company

Nintendo President on the new Switch 2, tariffs and what's next for the company

Continue Reading

Technology

Crypto firms urge UK to form national stablecoin strategy to avoid falling behind U.S.

Published

on

By

Crypto firms urge UK to form national stablecoin strategy to avoid falling behind U.S.

Stablecoin Tether and Circle’s USDC dominate the market.

Justin Tallis | Afp | Getty Images

The U.K. should establish a national stablecoin strategy to enable adoption of the tokens and avoid falling behind the U.S. on the disruptive new technology, several major crypto firms said Wednesday.

In an open letter addressed to Finance Minister Rachel Reeves, 30 crypto industry figures said that the U.K. “must act now to avoid being a rule-taker rather than a rule-maker in the digital asset era.”

“To ensure the UK is at the forefront, we believe a proactive, coordinated national strategy is needed – one that positions stablecoins not as a risk to be contained, but as a financial infrastructure to be responsibly embraced,” the letter said.

The U.K. Treasury department was not immediately available for comment when contacted by CNBC.

Stablecoins are a type of cryptocurrency that is pegged to an existing government-backed currency. There are several stablecoins in issuance, however the most commonly known are Tether’s USDT and Circle’s USDC — both of which are tied to the U.S. dollar.

The entire stablecoin market is worth over $280 billion, according to CoinGecko data. But for stablecoins pegged to the British pound, their combined market capitalization stands at just £461,224 ($621,197).

Crypto industry insiders have taken issue with Britain’s regulatory stance on stablecoins, saying it puts the nascent industry — and, in turn, the U.K.’s financial services landscape — at a disadvantage.

One aspect of the U.K.’s approach that worries the industry is the legal definition of stablecoins as “crypto-assets with reference to fiat currency.”

“This definition focuses on form rather than function,” they said in the open letter Wednesday. “This is akin to defining a cheque as paper with reference to currency, when both are essentially negotiable instruments backed by regulated issuers.”

A national stablecoin strategy would strengthen the U.K.’s role as a global financial center, generate new fee and foreign exchange revenue streams and support demand for gilts through new digital channels, the signatories to the letter said.

The letter was signed by industry executives from Coinbase, Kraken, Copper, Fireblocks, BitGo and VanEck.

Still, stablecoins are not without their concerns.

In 2022, a stablecoin named terra and its sister token luna both collapsed to $0 after a failure in the cryptocurrencies’ underlying technology. That also caused the value of USDT to temporarily fall below its $1 peg. USDT is currently worth $1.

In a research note published Wednesday, HSBC’s head of digital assets research, Daragh Maher, wrote that stablecoins could help bridge the gap between traditional finance and digital assets.

“They are basically the cash equivalent of digital assets,” Maher argued. “They are the reference or base currency for nearly every crypto asset. They can also be used for transferring money using blockchain pay rails rather than traditional banking methods.”

However, he added that regulatory issues remain the biggest hurdle to stablecoin adoption. “The key to capitalising on the potential of stablecoins lies in creating an appropriate regulatory environment for the sector,” said Maher.

How a $60 billion crypto collapse got regulators worried

Continue Reading

Trending